Allurion shares rise 11.29% intraday after partnering with Bionut to offer discounted Mounjaro in combination therapy.

Allurion Technologies (ALUR) surged 11.29% intraday after announcing a partnership with Bionut and Farmastar to provide discounted Mounjaro (tirzepatide) in combination with its Smart Capsule for weight loss treatment in Argentina. The collaboration, supported by clinical data showing 23% average total body weight loss at 12 months using low-dose tirzepatide, highlights Allurion’s expansion into the GLP-1-driven weight management market. The company emphasized improved patient adherence, reduced side effects, and cost savings, positioning the combination therapy as a competitive offering. Despite a Q3 2025 revenue decline to $2.7 million and ongoing U.S. investigational status for its Smart Capsule, the strategic move with Bionut—alongside recent partnerships in Brazil—underscores Allurion’s efforts to enhance market access and therapeutic outcomes, driving investor optimism.